More reproductive-age women with a diagnosis of cancer are receiving fertility preservation counseling from their doctors-but how many of those patients then decide to undergo fertility preservation? And how does their decision impact them later in life?
More reproductive-age women with a diagnosis of cancer are receiving fertility preservation counseling from their doctors-but how many of those patients then decide to undergo fertility preservation? And how does their decision impact them later in life?
Researchers at the University of California, San Francisco School of Medicine surveyed women from the California Cancer Registry from 1993 to 2007 who were aged 18 to 40 years at diagnosis. The results were presented at an oral and poster presentation at the Annual American Society for Reproductive Medicine Meeting in Denver.
Preliminary data from surveys returned revealed that, of the 285 women who underwent treatment with the potential to impact their fertility, 70% were counseled by an oncology team on the risk of cancer treatment to fertility, but only 9% saw a fertility specialist and only 8% underwent fertility preservation.
Women who had been advised about their fertility preservation options, had seen a fertility specialist, and who had fertility preservation suffered lower levels of regret than patients who did none of these. In addition, women who had performed fertility preservation showed noticeably more satisfaction with their lives.
Excessive gonadotropins in IVF: Effects on mosaicism and live birth
April 12th 2024A recent study revealed a correlation between high doses and prolonged duration of exogenous gonadotropin use during in vitro fertilization and increased embryonic mosaicism alongside diminished live birth rates, prompting reconsideration of dosage and duration protocols.
Read More
Metabolomics and proteomics linked to female infertility
January 30th 2024Dive into the latest research in metabolomics and proteomics, revealing potential biomarkers like fibrinogen cleavage peptides and GRAM domain-containing protein 1C, offering new avenues for diagnosis and treatment in addressing the global issue of female infertility.
Read More